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ABSTRACT
Ibrutinib, a clinically approved irreversible BTK kinase inhibitor for Mantle Cell 
Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) etc, has been reported to 
be potent against EGFR mutant kinase and currently being evaluated in clinic for Non 
Small Cell Lung Cancer (NSCLC). Through EGFR wt/mutant engineered isogenic BaF3 
cell lines we confirmed the irreversible binding mode of Ibrutinib with EGFR wt/mutant 
kinase via Cys797. However, comparing to typical irreversible EGFR inhibitor, such as 
WZ4002, the washing-out experiments revealed a much less efficient covalent binding 
for Ibrutinib. The biochemical binding affinity examination in the EGFR L858R/T790M 
kinase revealed that, comparing to more efficient irreversible inhibitor WZ4002 (Kd: 
0.074 µM), Ibrutinib exhibited less efficient binding (Kd: 0.18 µM). An X-ray crystal 
structure of EGFR (T790M) in complex with Ibrutinib exhibited a unique DFG-in/c-
Helix-out inactive binding conformation, which partially explained the less efficiency 
of covalent binding and provided insight for further development of highly efficient 
irreversible binding inhibitor for the EGFR mutant kinase. These results also imply that, 
unlike the canonical irreversible inhibitor, sustained effective concentration might be 
required for Ibrutinib in order to achieve the maximal efficacy in the clinic application 
against EGFR driven NSCLC. 
                  Research Paper
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INTRODUCTION
Ibrutinib, an irreversible BTK kinase inhibitor, 
has been extensively studied in the B-Cell related 
malignances due to the effective roles for interruption of 
the B-Cell Receptor (BCR) mediated signaling pathways 
[1, 2].  In late 2013 and early 2014 it has been approved 
for MCL and CLL clinical application respectively [3–6]. 
Currently it is also being actively evaluated in the clinic 
for the Diffuse Large B-Cell Lymphoma (DLBCL), 
Multiple Myeloma (MM) and Acute Myeloid Leukemia 
(AML) either as a single agent or combination with other 
chemotherapies or biological therapies [2, 7–9]. Recently 
Ibrutinib has also been reported to be effective against 
EGFR mutant Non-Small Cell Lung Cancer (NSCLC) 
and now being tested in phase I/II clinical trial.[10] 
Ibrutinib forms a covalent bond with BTK kinase in the 
Cys481 amino acid to exert the irreversible binding.[11] 
Proteomic study with ABPP approach also demonstrated 
that ibrutinib could modify the EGFR wide type kinase 
via Cys797 in A431 cells [12]. Given the clinical 
importance of EGFR mutant driven NSCLC, we explored 
the detailed binding mechanism of Ibrutinib with 
mutant EGFR (L858R, Del19, L858R/T790M) which 
revealed a relatively less efficient irreversible binding 
due to a unique DFG-in/c-Helix-out inactive binding 
conformation. We envision that insight of this special 
binding mechanism may help to develop more effective 
Ibrutinib pharmacophore based EGFR mutant sensitive 
inhibitors for NSCLC and also direct the proper design of 
the clinical trial to achieve the maximal efficacy. 
RESULTS
Ibrutinib irreversibly binds to EGFR mutant via 
Cys797
Given the fact that both EGFR and BTK kinase 
bear a similarly accessible cysteine residue (Cys481 in 
BTK and Cys797 in EGFR) in the hinge binding area, 
we first tried to determine if ibrutinib binds irreversibly 
to EGFR mutant as it binds to BTK kinase [13]. We 
first made a panel of EGFR wt/mutant engineered 
BaF3 isogenic cell lines whose growth is dependent 
on either TEL fusion with the EGFR kinase domain 
(TEL-EGFR) or full-length EGFR (F-EGFR) harboring 
gain-of-function mutations with or without the Cys797 
mutation (C797S).[14] Ibrutinib did not affect wt EGFR-
expressing BaF3 cells, wt TEL-EGFR, or the TEL-EGFR 
(C797S) mutation (GI50: > 10 μM). (Table 1)  It potently 
inhibited the TEL-EGFR (L858R) (GI50: 0.062 μM) 
mutation, however significantly lost activity against TEL-
EGFR (L858R/C797S) (GI50: 3.9 μM). It also exhibited 
activity against TEL-EGFR (T790M) (GI50: 0.16 μM), 
however lost around 10-fold potency against TEL-EGFR 
(L858R/T790M) (GI50: 1.7 μM). Ibrutinib completely 
lost activity against cell lines harboring the EGFR C797S 
mutation. Interestingly, Ibrutinib was approximately 10-
fold more potent against full length F-EGFR (L858R) 
transformed BaF3 cells than the TEL-EGFR (L858R) 
(GI50: 0.004 μM vs. 0.062 μM).  Similarly, ibrutinib lost 
around 10-fold activity against F-EGFR (L858R/T790M) 
(GI50: 0.061 μM) and also significantly lost activity 
when C797S was introduced (GI50: 3.8 μM).  A similar 
trend was observed for the EGFR (Del 19) mutation. 
These results recapitulated the results observed from 
the intact cancer cell lines and suggest that ibrutinib is 
highly potent against EGFR (L858R) and EGFR (Del 
19) mutations, however moderately active when the 
T790M gatekeeper mutation is introduced.  Comparably, 
the reversible version of ibrutinib, i.e. PCI-R, lost 
approximately 20–50 fold activities as compared to 
ibrutinib itself. (Supplementary Figure S1) Combining 
the results observed with ABPP approach for EGFR wt 
in A431 cells, these results suggest that ibrutinib works 
through formation of a covalent bond with Cys797. 
Irreversible EGFR inhibitors WZ4002, CO-1686 and 
AZD9291 demonstrated similar activities, except they 
also moderately inhibited the growth of wt EGFR-
expressing BaF3 cells, indicating potential off-target 
effects. While reversible EGFR inhibitor exhibited 
similar trend with PCI-R except that it also potently 
inhibits the EGFR L858R mutant. 
Washing-out experiment revealed ibrutinib’s less 
irreversible inhibition efficiency
To further elucidate the possible irreversible 
binding mode, we then conducted a washing-out 
experiment in H1975 cell (EGFR L858R/T790M) using 
an anti-proliferation assay. The results showed that 
WZ4002 worked as a typical irreversible inhibitor that 
exhibited apparent inhibitory activity after even just 
1 h pre-drug treatment. However, ibrutinib only exhibited 
inhibitory activities upon 72 h continuous drug treatment. 
(Figure  1A) With 4 h pre-drug treatment in the H1975 
cell line, WZ4002 (0.3 μM) completely suppressed 
EGFR Y1068 auto-phosphorylation within 24 h after 
drug removal. However, at the GI50 concentration (1 μM) 
of ibrutinib, the EGFR Y1068 auto-phosphorylation 
signal returned following 8 h after drug removal, 
which suggests a less efficient irreversible inhibition. 
(Figure 1B) The similar phenotype was observed in the 
HCC827 cell that harbors EGFR del19 deletion despite of 
the strong in vitro anti-proliferation efficacy comparing 
to H1975 cells. (Figure 1C, 1D) These results indicated 
that ibrutinib was a unique irreversible EGFR inhibitor 
comparing to other typical ones and its inhibitory efficacy 
might require sustained drug exposure to maintain 
the signaling pathway suppression. Further testing 
biochemical binding affinity of ibrutinib with purified 
EGFR L858R/T790M kinase protein revealed that it 
Oncotarget69762www.impactjournals.com/oncotarget
beard a binding Kd of 0.18 μM, while  more efficient 
irreversible inhibitor WZ4002 displayed a binding Kd 
of 0.074 μM. (Figure 1E) This indicated that the less 
efficiency of the irreversible binding might be due to the 
less efficient binding. 
Ibrutinib adopted a unique DFG-in/c-Helix-out 
inactive binding conformation 
To further explore this special phenotype, we 
determined a high-resolution crystal structure of EGFR 
Table 1: Ibrutinib anti-proliferation efficacy against EGFR mutant isogenic BaF3 cell lines
Isogenic Cell 
Line
GI50(μM)
WZ-4002 Gefitinib Ibrutinib PCI-R CO-1686 AZD9291
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WT-BaF3 > 10 > 10 > 10 7.5 0.97 2.7
BaF3-tel-wt-
EGFR 1.6 5.2 > 10 > 10 2.8 1.8
BaF3-tel-WT-
EGFR-C797S 1.3 0.11 > 10 > 10 1.3 1.3
BaF3-tel-
EGFR-L858R 0.0023 0.0022 0.062 4.7 0.0063 0.0017
BaF3-tel-
EGFR-L858R-
C797S
3.7 0.006 3.9 9.3 1.6 0.6
BaF3-tel-
EGFR-T790M 0.11 > 10 0.16 > 10 0.13 0.022
BaF3-tel-
EGFR-T790M-
C797S
> 10 > 10 >10 > 10 1.2 1.6
BaF3-tel-
EGFR-L858R-
T790M
0.0012 2.8 1.7 3.1 0.038 0.007
BaF3-tel-
EGFR-T790M-
L858R-C797S
4.5 > 10 > 10 > 10 0.88 1.7
BaF3-FL-
EGFR-L858R 0.003 0.007 0.004 2.1 0.015 0.002
BaF3-FL-
EGFR-L858R-
T790M
0.0017 7.2 0.061 1.3 0.0014 0.0021
BaF3-FL-
EGFR-T790M-
L858R-C797S
1.2 3.7 3.8 3.5 0.73 1.7
BaF3-FL-
EGFR-del19-
T790M
0.0016 2.9 0.34 1.1 < 0.0003 < 0.0003
BaF3-FL-
EGFR-del19-
T790M-C797S
0.83 1.6 > 10 > 10 0.63 0.36
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Figure 1: Ibrutinib irreversible binding mode exploration. (A) Ibrutinib and WZ4002 anti-proliferation effects against the 
H1975 cell line by removal of drug after 1 h, 4 h and 72 h treatment. (B) Ibrutinib and WZ4002 inhibitory effects on EGFRY1068 auto-
phosphorylation in the H1975 cell line at different time points by removal of drug after 4 h pretreatment. (C) Ibrutinib and WZ4002 anti-
proliferation effects against the HCC827 cell line by removal of drug after 1 h, 4 h and 72 h treatment. (D) Ibrutinib and WZ4002 inhibitory 
effects on EGFRY1068 auto-phosphorylation in the HCC827 cell line at different time points by removal of drug after 4 h pretreatment. 
(E) Micro-Scale Thermophoresis (MST) technology  based binding Kd test of Ibrutinib and WZ4002 against EGFR T790M/L858R kinase.
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T790M in complex with ibrutinib (PDB ID: 4YNJ, 
Table 2 and Supplementary Figure S2). Covalent binding 
of ibrutinib to EGFR Cys797 was confirmed in this 
structure, and we found that Ibrutinib binds EGFR T790M 
in inactive conformation, although this protein by 
itself crystallizes in active conformation [15]. Four 
EGFR T790M protein molecules were observed in the 
asymmetric unit of the T790M+Ibrutinib structure, 
each binding to an ibrutinib molecule. (Figure 2A) 
Interestingly, despite the same covalent bonds formed 
between the Cys797 of EGFR and acrylamide of ibrutinib, 
the four ibrutinib molecules adopt two slightly different 
conformations in the piperidine-acrylamide moiety. 
(Figure 2B) The ibrutinib bound EGFR T790M adopts the 
DFG-in/C-helix-out inactive conformation which closely 
resembles the previously reported EGFR structure in 
inactive conformation (PDB ID 2GS7, Figure 2C) [16]. 
The Met790 side-chain well fits to the inhibitor and make 
beneficial hydrophobic interaction with the phenyl ring 
attached to pyrazolopyrimidine. (Figure 2C) This may 
explain the relative tolerance of ibrutinib to the drug-
resistant T790M-bearing EGFR mutants comparing to the 
first generation inhibitor Gefitinib. 
Since HKI-272 also covalently binds to EGFR in 
the inactive conformation, we compared the structure of 
EGFR T790M in complex with ibrutinib to the structure 
of EGFR T790M in complex with HKI-272 [15]. Two 
major differences were revealed in the superimposition 
(Figure 2D) First, the beneficial interaction between 
Met790 side-chain and the phenyl ring attached to the 
Table 2: Data collection and refinement statistics
T790M + Ibrutinib*
Data collection**
Space group C2
Cell dimensions
 a, b, c (Å) 168.2, 74.4, 120.5
 (°) 90.0, 118.3, 90.0
Resolution (Å) 50.0–1.95 (2.02–1.95)
Rpim 0.095 (0.450)
I/I 7.9 (2.3)
Completeness (%) 99.6 (99.8)
Redundancy 3.2 (3.2)
Refinement
Resolution (Å) 41.6–1.95
No. reflections 94949
Rwork/Rfree 0.200/0.221
No. atoms
 Protein 9690
 Ligand/ion 156
 Water 950
B-factors
 Protein 28.4
 Ligand/ion 24.0
 Water 37.7
R.m.s. deviations
 Bond lengths (Å) 0.010
 Bond angles (°) 1.403
PDB ID 4YNJ
*One crystal was used to collect data for determination of this structure.
**Values in parentheses are for highest-resolution shell.
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pyrazolopyrimidine moiety of ibrutinib does not present 
in the HKI-272 bound EGFR T790M structure. The 
cyano group attached to the quinolone moiety in HKI-272 
prevents this beneficial interaction due to steric hindrance. 
Second, Ibrutinib does not interact with Phe856 in the 
DFG motif as HKI-272 and Lapatinib do [15, 17]. One 
more methylene group presents in the linkage between 
the terminal pyridine ring and the phenyl ring attached to 
the quinolone moiety in HKI-272 (similar design applies 
to Lapatinib). This extra methylene pushes the terminal 
pyridine (phenyl in the case of Lapatinib) more deeply 
into the ATP binding pocket, driving it close to the DFG 
motif. The terminal phenyl thus makes direct hydrophobic 
interaction with Phe856. This interaction is not observed 
with ibrutinib since its terminal phenyl ring does not go 
deeply enough in the ATP binding pocket. This explains 
why ibrutinib binds EGFR in a distinct DFG-in/C-helix-
out conformation, while HKI-272 (and Lapatinib) binds 
EGFR in a DFG-partially-out/C-helix-out conformation. 
The relatively weaker binding affinity of ibrutinib to 
EGFR(L858R/T790M) may be related to this property, 
too, since the inhibitor-DFG interaction would enhance 
the binding of the drug. 
WZ4002 is another third-generation covalent 
inhibitor that works well with EGFR T790M. 
Superimposition of the T790M+Ibrutinib structure with 
the previously reported T790M+WZ4002 co-crystal 
structure (PDB ID 3IKA) [18–21] disclosed the distinct 
difference between these two inhibitors. Ibrutinib forces 
EGFR kinase to adopt a distinct DFG-in/C-helix-out 
inactive conformation.  While WZ4002 binds to the DFG-
partially-out/C-helix-in active conformation.  (Figure 2E) 
The bulky o-bridged biphenyl moiety of ibrutinib can 
be accommodated by EGFR in the inactive state only, 
Figure 2: Crystal structure of EGFR T790M+ibrutinib and the comparison with other EGFR T790M+inhibitor 
co-crystal structures. (A) Chemical structures of Ibrutinib, HKI-272, Lapatinib and WZ4002 shown in the orientation roughly indicating 
their binding mode to EGFR. “Hinge” indicates the hinge peptide of EGFR that connects N-lobe and C-lobe of the kinase and interacts 
with the inhibitors through hydrogen bonds (indicated by dashed lines). The green arrows indicate the extra methylene in HKI-272 and 
Lapatinib. The purple arrow indicates the cyano group of HKI-272. (B) Superimposition of the four molecules in the asymmetric unit of the 
EGFR T790M+ibrutinib co-crystal structure. The red arrows indicate the slight difference between the two binding modes of ibrutinib. (C) 
Superimposition of the EGFR T790M+ibrutinib structure (slate) and the V948R+AMP-PnP structure (drawn from PDB ID 2GS7, cyan). 
(D) Superimposition of the EGFR T790M+ibrutinib structure (slate) and the T790M+HKI-272 structure (yellow). The double-headed 
orange arrow indicates the hydrophobic interaction between the inhibitor and the Phe856 side-chain. (E) Superimposition of the EGFR 
T790M+ibrutinib structure (slate) and the T790M+WZ4002 structure (green).
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while WZ4002 can bind to EGFR in active state and 
probably also in inactive state. What’s more, to push the 
EGFR kinase from the ligand binding or mutation (such 
as L858R) induced active conformation toward inactive 
conformation would cost extra energy. These may explain 
why ibrutinib binds to EGFR less efficiently than does 
WZ4002.
DISCUSSION
Therefore, we postulated that the transient 
inhibitory activity of Ibrutinib against mutant EGFR 
Y1068 phosphorylation might be due to the distinct 
irreversible binding conformation formation since it 
required more binding energy to force the protein to 
adopt the DFG-in/c-Helix-out conformation.  This 
phenotype is concentration dependent. At the same 
drug concentration, after removal of the drugs from 
the medium during the washing-out experiment, 
drug molecules that have already fitted the protein 
conformation while not yet formed the covalent bond 
would stay in the protein for longer time (residence 
time) since the protein required more energy to recover 
back to the normal state but eventually the drug will 
be released out from the protein complex due to the 
equilibrium between the inner cell and cell culture 
medium. This could explain why during the first several 
hours the phosphorylation of EGFR was continuously 
inhibited but then gradually got recovered then.  In 
summary, the less efficiency of sustained inhibition of 
EGFR phosphorylation was due to the less efficient 
binding of ibrutinib to EGFR, but the distinct binding 
conformation gave ibrutinib a longer residence time on 
EGFR kinase, those ibrutinib molecules which did not 
form the covalent bond would be gradually released 
from the protein and hence resulted in the partial of 
the kinase activity recovery. Therefore an alternative 
Ibrutinib pharmacophore based scaffold would be needed 
in order to more efficiently stable the DFG-in/c-Helix 
out conformation and exert better-sustained inhibitory 
efficacy for the Y1068 site phosphorylation. 
In summary, Ibrutinib inhibits mutant EGFR 
kinase through formation a covalent bond with 
Cys797, as other irreversible inhibitors, but due to an 
unusual DFG-in/c-Helix-out binding conformation, 
this irreversible binding is much less efficient than 
other irreversible EGFR inhibitors such as WZ4002. 
Considering the evidence that ibrutinib is highly potent 
in in vitro for EGFR mutant NSCLC cancer cell lines 
but only moderately slow down tumor progression in 
the mouse model, we propose that without alteration 
of the PK property of Ibrutinib itself, a specially 
designed formulation or dosage which can help sustain 
effective concentration should be considered to achieve 
the efficacy in the clinic application for mutant EGFR 
driven NSCLC. 
MATERIALS AND METHODS
Inhibitors
Ibrutinib, W4002, CO-1686, AZD9291, Gefitinib 
were purchased from Haoyuan Chemexpress Inc.  PCI-R 
was synthesized in the lab based on the procedure reported 
previously [1]. 
Cell lines and cell culture 
The human cancer cell lines H1975, HCC827, 
and A549 cells were purchased from the American Type 
Culture Collection (ATCC) (Manassas, VA, USA). A431 
was purchased from Cobioer Biosciences CO., LTD 
(Nanjing, China). H1975, HCC827 and EGFR mutant 
isogenic BaF3 cells lines were cultured in RPMI 1640 
media (Corning, USA) with 10% fetal bovine serum 
(FBS) and supplemented with 2% L-glutamine and 1% 
penicillin/streptomycin. A549 was cultured in F-12K 
Nutrient Mixture (kaighn’s Modification) (Gibco, USA), 
and A431 was cultured in DMEM media (Corning, USA) 
with 10% FBS and supplemented with 2% L-glutamine 
and 1% pen/strep. H3255 was cultured in BEGM media 
(LONZA, USA) with 10% FBS and supplemented with 
2% L-glutamine and 1% pen/strep. All cell lines were 
maintained in culture media at 37ºC with 5% CO2.
Antibodies and immunoblotting 
The following antibodies were purchased from Cell 
Signaling Technology (Danvers, MA): EGF Receptor 
(D38B1) XP® Rabbit mAb(#4267), Phospho-EGF 
Receptor (Tyr1068) (D7A5) XP® Rabbit mAb (#3777), 
Antibodies were used at 1:1000.
BaF3 isogenic cell line generation 
Retroviral constructs for Ba/F3-TEL-EGFR and Ba/
F3-EGFR variants were made based on the pMSCVpuro 
(Clontech) backbone. For TEL-fusion vectors, the first 
1 kb of human TEL gene with  an artificial  myristoylation 
sequence  (MGCGCSSHPEDD)  was  cloned  into 
pMSCVpuro retroviral vector, followed by a 3xFLAG tag 
sequence and a stop codon. Then the kinase domain coding 
sequences of EGFR variants were inserted in-frame between 
TEL and 3xFLAG sequences. For full-length expression 
vectors, the coding sequences of EGFR variants were 
directly cloned in pMSCVpuro vector with a 3xFLAG tag 
at the C-terminal end. All mutations were performed using 
the QuikChange Site-Directed Mutagenesis Kit (Stratagene) 
following the manufacturer’s instructions. Retrovirus was 
made using the same method described above and was used 
to infect BaF3 cells. After puromycin selection, the IL-3 
concentration in the medium was gradually withdrawn until 
cells were able to grow in the absence of IL-3.
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Proliferation studies
Cells were grown in 96-well culture plates 
(2500–3000/well). For adherent cell lines, compounds of 
various concentrations were added into the plates after 
cells were cultured for 12 hours. Cell proliferation was 
determined after treatment with compounds for 72 hours. 
Cell viability was measured using the CellTiter–Glo 
assay (Promega, USA), according to the manufacturer’s 
instructions, and luminescence was measured in a multi-
label reader  (Envision, PerkinElmer, USA). Data were 
normalized to control groups (DMSO) and represented 
by the mean of three independent measurements with 
standard error < 20%. GI50 values were calculated using 
Prism 5.0 (GraphPad Software, San Diego, CA).
Washing out experiment
H1975 cells were treated with ibrutinib (0.3 μM, 
1 μM , 3 μM), WZ4002 (0.3 μM, 1 μM) for 4 hour 
before they were thoroughly washed out by PBS for three 
times. Then cells were incubated in 10% FBS-containing 
RPMI1640 for indicated time before they are collected and 
lysed. EGFR, Phospho-EGFR (Tyr1068) antibody (Cell 
Signaling Technology) were used for immunoblotting.
EGFR (L858R/T790M) protein purification
A construct encoding EGFR residues 696–1022 with 
a GST tag was cloned into baculovirus expression vector 
pAcG2T. The protein was expressed by infecting SF9 cells 
with high titer viral stocks for 48 h. Cells were harvested 
and lysed in 25 mM Tris (pH 7.9), 150 mM NaCl, 
and 1 mM DTT. The supernatant was incubated with 
glutathione Sepharose beads (Genscript). After washing 
with wash buffer (40 mM Tris pH 7.9, 500 mM NaCl, 1% 
Glycerol, 1 mM DTT), the beads were incubated overnight 
with 5 ml wash buffer containing 5 ul of 5 mg/ ml alpha-
thrombin to remove GST tag. The eluted EGFR protein 
was loaded on desalt column PD-10(GE) to change the 
buffer to 25 mM Tris pH7.5, 50 mM NaCl, 20 mM MgCl2, 
and 1 mM DTT. The protein was concentrated to 1 mg/ml 
and aliquots were frozen and stored at −80°C.
Biochemical binding Kd examination 
The Kd was measured using the Monolith 
NT.115 from Nanotemper Technologies. Proteins were 
fluorescently labeled according to the manufacturer’s 
protocol. A range of concentrations of ligands Ibrutinib 
and WZ4002 (range from 0.05 mM to 2.5 nM) 
were incubated with 200 nM of purified EGFR T790M/
L858R protein 5 min in assay buffer (50 mM Tris, 
200 mM NaCl, PH7.4, and 0.05% Tween 20). The sample 
was loaded into the NanoTemper glass capillaries and 
microthermophoresis carried out using 20% LED power 
and 20% MST Power. Kd were calculated using the mass 
action equation via the NanoTemper software.
Protein preparation and crystallization
Construct of EGFR kinase domain (residues 
696–1022) bearing the T790M mutation was PCR-cloned 
from the previously made GST-tagged EGFR T790M 
construct [15] and inserted into pFastBac HTA plasmid 
between the NcoI and XhoI restriction sites. Baculoviruse 
expressing the His-tagged EGFR 696–1022 T790M 
protein was then generated according to the official 
protocols of the pFastBac. 
The His-tagged EGFR 696-1022 T790M protein was 
expressed in Sf9 insect cells. After harvesting, the cells 
were broken by sonication in lysis buffer (20 mM Tris, 
150 mM NaCl, 3 mM KCl, 10% glycerol, 1 mM PMSF, 
1 mM TCEP, 20 mM Imidazole, pH 8.0, supplemented 
with Protease Inhibitors Cocktail (Sigma-Aldrich, Cat. 
S8830). Cell lysate was obtained by centrifugation 
at 20,000 rpm for 1 hour at 4°C and then applied to 
the chelating sepharose beads (GE Healthcare, Cat. 
17-0575-02) charged with Ni2+. The beads were thoroughly 
washed with wash buffer (20 mM Tris, 500 mM NaCl, 1% 
glycerol, 0.5 mM TCEP, 30 mM Imidazole, pH 8.0), and 
then the protein was eluted with elution buffer (20  mM 
Tris, 500 mM NaCl, 1% glycerol, 0.5 mM TCEP, 300 mM 
Imidazole, pH 8.0). The affinity tags were removed 
by cleavage with TEV protease for 3 hours at 4°C, and 
the untagged EGFR proteins were collected from the 
flow-through of another pass through the Ni-beads. The 
eluent was concentrated and applied to gel-filtration 
chromatography using a Superdex 200 column (GE 
Healthcare, Cat. 17-5175-01) to further purify the protein. 
The purified protein was concentrated and dispensed into 
aliquots, flash-frozen in liquid nitrogen and stored in 
−80°C freezer for later using.
For co-crystalization, 100 mM ibrutinib solution 
was added to 8.8 mg/mL EGFR T790M protein solution 
to achieve the final concentration of 1 mM compound. The 
mixture was incubated on ice for 2 hours to enable full 
labeling of EGFR with the compound before setting up the 
crystallization tray. The crystallization reservoir solution 
for T790M+ibrutinib was 0.1 M sodium citrate (pH 5.0), 
12% PEG 10000, and 3% dioxane, 5 mM TCEP.
Crystal structure determination and refinement 
The T790M+ibrutinib co-crystal diffraction data 
were collected at beamline BL17U1, Shanghai Synchrotron 
Radiation Facility at 100K. The X-ray wavelength for 
data collection was 0.97930Å. The diffraction data 
were processed with HKL3000 [22]. The structure was 
solved by molecular replacement method with Phaser 
[23] using isolated N-lobe and C-lobe of the previously 
reported EGFR T790M structure (PDB 3IKA) as the 
Oncotarget69768www.impactjournals.com/oncotarget
search models. Simulated-annealing in CNS [24] was then 
used to obtain a less biased model and 2Fo-Fc and Fo-Fc 
maps for manual inspection and adjustment. Repeated 
rounds of manual refitting and crystallographic refinement 
were performed using COOT [25] and Phenix [26]. The 
inhibitor was modeled into the closely fitting positive 
Fo-Fc electron density and then included in following 
refinement cycles. Topology and parameter files for the 
inhibitors were generated using PRODRG [27]. Reported 
by Ramachandran plots, the percentages of residues in the 
favored and allowed regions for the final refined structure 
are 98.1% and 1.9%, respectively. No residues are in the 
outlier region. The structure was deposited in Protein Data 
Bank (PDB) with the entry IDs 4YNJ.
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